Aclaris Therapeutics, Inc. ACRS
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +31.89%
- 1 year
- +59.44%
- Open
- 4.02
- Prev close
- 3.99
- Mkt cap
- 615.29M
- Vol
- 1.88M
- Avg vol
- 2.91M
- EPS
- -0.58
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.87
- High
- 4.07
- Forward P/E
- -5.00
- Beta
- 0.12
- Short ratio
- 0.47
- Inst. own
- 90.21%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.70
- 200-d avg
- 1.58
- 1y target
- 10.00
Key statistics
- Market cap
- 310.36M
- Enterprise value
- 68.82M
- Trailing P/E
- 0.00
- Forward P/E
- -5.00
- PEG ratio
- 0.00
- Price / sales
- 11.46
- Price / book
- 1.59
- EPS (TTM)
- -0.52
- Beta
- 0.12
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -136.65%
- Revenue (TTM)
- 27.08M
- Revenue growth
- -53.20%
- Free cash flow
- -22.05M
- Total cash
- 127.72M
- Total debt
- 2.25M
- Return on equity
- -25.83%
- Shares outstanding
- 107.02M
- Short % of float
- 4.14%
- 50-day average
- 2.70
- 200-day average
- 1.58
Analyst view
Consensus: buy
- Target (low)
- 5.00
- Target (mean)
- 10.00
- Target (high)
- 20.00
- Strong buy2
- Buy3
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.324.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.08 | -0.11 | -0.03 | -37.50% |
| Aug 7, 2024 | Jun 1, 2024 | -0.19 | -0.15 | +0.04 | +21.05% |
| May 7, 2024 | Mar 1, 2024 | -0.28 | -0.24 | +0.04 | +14.29% |
| Feb 27, 2024 | Dec 1, 2023 | -0.37 | -0.30 | +0.07 | +18.92% |
| Nov 6, 2023 | Sep 1, 2023 | -0.48 | -0.41 | +0.07 | +14.58% |
| Aug 7, 2023 | Jun 1, 2023 | -0.45 | -0.42 | +0.03 | +6.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | HC Wainwright & Co. | up | Neutral | Buy |
| Nov 19, 2024 | Leerink Partners | up | Market Perform | Outperform |
| Nov 19, 2024 | Jefferies | up | Hold | Buy |
| Nov 19, 2024 | BTIG | up | Neutral | Buy |
| Nov 18, 2024 | Piper Sandler | up | Neutral | Overweight |
| Sep 17, 2024 | HC Wainwright & Co. | reit | — | Neutral |
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- aclaristx.com
News
- Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Raises Price Target to $13
- Wedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8
- HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target
- Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b
- Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma Drug
- Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript
- Whirlpool Posts Downbeat Q3 Results, Joins HSBC, Hilton Hotels And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
- Aclaris Therapeutics Prices $50M Offering Of 7,785,714 Shares And Warrants To Purchase 6.5M Shares At $3.50/Unit
- Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
- Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma
Your note
Sign in to keep a note on ACRS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BALTHASER KEVIN J | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 29, 2024 | 24,697 |
| HUMPHRIES WILLIAM DOUGLAS | Director | Conversion of Exercise of derivative security | May 30, 2024 | 28,732 |
| LEONARD BRADEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 4, 2024 | 0 |
| MEHRA ANAND | Director | Purchase | Nov 18, 2024 | 710,030 |
| MILANO VINCENT J | Director | Conversion of Exercise of derivative security | May 30, 2024 | 12,523 |
| MOLINEAUX CHRISTOPHER P | Director | Conversion of Exercise of derivative security | May 30, 2024 | 53,163 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BML Capital Management, LLC | 13.32% | 14,250,000 | 41.33M | Sep 29, 2024 |
| Vanguard Group Inc | 4.38% | 4,685,498 | 13.59M | Sep 29, 2024 |
| Shaw D.E. & Co., Inc. | 3.15% | 3,371,849 | 9.78M | Sep 29, 2024 |
| Millennium Management Llc | 2.81% | 3,005,598 | 8.72M | Sep 29, 2024 |
| Rock Springs Capital Management, LP | 2.57% | 2,753,495 | 7.99M | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 2.30% | 2,458,873 | 7.13M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.98% | 2,115,428 | 6.13M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.77% | 820,732 | 2.38M | Sep 29, 2024 |
| Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 0.66% | 706,504 | 2.05M | Sep 29, 2024 |
| Vanguard Variable Insurance Fund-Small Company Growth | 0.60% | 639,021 | 1.85M | Sep 29, 2024 |
| iShares Biotechnology ETF | 0.46% | 491,473 | 1.43M | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.38% | 403,786 | 1.17M | Oct 30, 2024 |